Audited Financial Results for the quarter and year ended 31 March, 2026
MARKSANS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Marksans Pharma reported consolidated revenue of Rs 29,509 million for FY2026, up 12.5% from Rs 26,228 million in FY2025. Profit after tax grew 9.8% to Rs 4,201 million from Rs 3,826 million. Diluted EPS improved to Rs 9.22 from Rs 8.40. The company declared an unmodified audit opinion from MSKA & Associates. The Board recommended a final dividend of Rs 0.90 per share (90%) for FY2025-26, subject to shareholder approval. The company expanded globally with two new wholly-owned subsidiaries formed in Ireland and Canada in January 2026.
Strong double-digit revenue and profit growth with clean audit opinion and dividend declaration are positive signals for shareholders. The stock could see renewed interest given the consistent financial performance and global expansion.